Stephens analyst George Sellers raised the firm’s price target on Teleflex to $295 from $280 and keeps an Overweight rating on the shares. After valuations peaked in Med Tech in 2021, they declined throughout most of 2022 and after a volatile year he expects many medical device companies to use Q4 earnings season and conferences early in the year to reset expectations for 2023 lower, Sellers tells investors. While this is a headline risk to many of the companies he covers, he believes resetting expectations will allow companies to return to an environment where estimates trend higher throughout the year, Sellers added. Into 2023, he prefers companies that either expect to receive FDA approval for a device or treatment or that are new entrants to an existing market or geography, the analyst noted.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TFX:
- Teleflex to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Teleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift® System
- Craig-Hallum sees potential for competing Apollo Endosurgery bids
- Teleflex Earns Top Spot in MedReps Best Places to Work 2023 Ranking
- Teleflex to Present at the 34th Annual Piper Sandler Healthcare Conference